Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)John Mascarenhas, Robert S. Hoffman, Murat O. Arcasoy et al.|Blood|2018Cited by 45
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas, Robert S. Hoffman, Josef T. Prchal et al.|Blood|2016Cited by 28
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III TrialRuben A. Mesa, Amylou C. Dueck, Heidi Kosiorek et al.|Blood|2018Cited by 12
Autologous Peripheral Blood Stem Cell Transplantation in First Remission Adult Acute Myeloid Leukaemia--An Intention to Treat Analysis and Comparison of Outcome Using a Predictive Model Based on the MRC AML10 CohortJoanne Ewing, R Chopra, Jane Robertson et al.|Hematology|2003Cited by 5
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line SettingsAbdulraheem Yacoub, Robert S. Hoffman, Ruben A. Mesa et al.|Blood|2019Cited by 5